Oxford BioMedica (OXBDF)
(Delayed Data from OTC)
$4.48 USD
+0.04 (0.79%)
Updated Jul 22, 2024 03:22 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Balance Sheet
Fiscal Year End for Oxford BioMedica falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 175 | 150 | 60 | 21 |
Receivables | NA | 76 | 62 | 69 | 45 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 16 | 13 | 9 | 3 |
Other Current Assets | NA | 0 | 0 | 0 | 3 |
Total Current Assets | NA | 267 | 225 | 139 | 73 |
Net Property & Equipment | NA | 165 | 96 | 93 | 79 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 6 | 5 | 5 | 5 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 131 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 569 | 326 | 236 | 157 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 45 | 26 | 25 | 18 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 4 | 1 | 6 | 1 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 1 | 0 | 0 | 0 |
Other Current Liabilities | NA | 24 | 18 | 36 | 18 |
Total Current Liabilities | NA | 74 | 46 | 67 | 37 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 8 | 2 | 3 | 5 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 49 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 88 | 12 | 12 | 10 |
Other Non-Current Liabilities | NA | 58 | 9 | 9 | 9 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 277 | 69 | 91 | 60 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 60 | 59 | 53 | 49 |
Capital Surplus | NA | 470 | 423 | 331 | 284 |
Retained Earnings | NA | -246 | -228 | -242 | -240 |
Other Equity | NA | 8 | 3 | 3 | 3 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 292 | 258 | 145 | 97 |
Total Liabilities & Shareholder's Equity | NA | 569 | 326 | 236 | 157 |
Total Common Equity | 0 | 292 | 258 | 145 | 97 |
Shares Outstanding | 96.20 | 96.20 | 76.80 | 76.80 | 76.80 |
Book Value Per Share | 0.00 | 3.04 | 3.35 | 1.89 | 1.26 |
Fiscal Year End for Oxford BioMedica falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | -99,999 | -99,837 |
Receivables | NA | NA | NA | NA | 43 |
Notes Receivable | NA | NA | NA | NA | NA |
Inventories | NA | NA | NA | NA | 17 |
Other Current Assets | NA | NA | NA | NA | 0 |
Total Current Assets | NA | NA | NA | NA | 222 |
Net Property & Equipment | NA | NA | NA | NA | 151 |
Investments & Advances | NA | NA | NA | NA | NA |
Other Non-Current Assets | NA | NA | NA | NA | 6 |
Deferred Charges | NA | NA | NA | NA | NA |
Intangibles | NA | NA | NA | NA | 123 |
Deposits & Other Assets | NA | NA | NA | NA | NA |
Total Assets | NA | NA | NA | NA | 502 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | NA |
Accounts Payable | NA | NA | NA | NA | 33 |
Current Portion Long-Term Debt | NA | NA | NA | NA | NA |
Current Portion Capital Leases | NA | NA | NA | NA | 5 |
Accrued Expenses | NA | NA | NA | NA | NA |
Income Taxes Payable | NA | NA | NA | NA | 1 |
Other Current Liabilities | NA | NA | NA | NA | 29 |
Total Current Liabilities | NA | NA | NA | NA | 67 |
Mortgages | NA | NA | NA | NA | NA |
Deferred Taxes/Income | NA | NA | NA | NA | 8 |
Convertible Debt | NA | NA | NA | NA | NA |
Long-Term Debt | NA | NA | NA | NA | 48 |
Non-Current Capital Leases | NA | NA | NA | NA | 89 |
Other Non-Current Liabilities | NA | NA | NA | 42 | |
Minority Interest (Liabilities) | NA | NA | NA | NA | NA |
Total Liabilities | NA | NA | NA | NA | 254 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | NA |
Common Stock (Par) | NA | NA | NA | NA | 60 |
Capital Surplus | NA | NA | NA | NA | 476 |
Retained Earnings | NA | NA | NA | NA | -306 |
Other Equity | NA | NA | NA | NA | 18 |
Treasury Stock | NA | NA | NA | NA | NA |
Total Shareholder's Equity | NA | NA | NA | NA | 248 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | NA | 502 |
Total Common Equity | 0 | 0 | 0 | 0 | 100,247 |
Shares Outstanding | 96.20 | 96.20 | 96.20 | 96.20 | 96.20 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 1,042.07 |